LUPIN:NSE:NSE-Lupin Limited (INR)

COMMON STOCK | Drug Manufacturers - Specialty & Generic |

Last Closing

USD 1923.05

Change

-48.00 (-2.44)%

Market Cap

USD 925.89B

Volume

1.99M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-07 )

Largest Industry Peers for Drug Manufacturers - Specialty & Generic

Symbol Name Price(Change) Market Cap
DIVISLAB:NSE Divi's Laboratories Limited

+19.50 (+0.34%)

USD 1,533.20B
CIPLA:NSE Cipla Limited

+14.60 (+0.99%)

USD 1,164.75B
TORNTPHARM:NSE Torrent Pharmaceuticals Limite..

+0.90 (+0.03%)

USD 1,092.48B
MANKIND:NSE Mankind Pharma Ltd

+93.90 (+3.87%)

USD 1,000.40B
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

+3.50 (+0.30%)

USD 953.29B
ZYDUSLIFE:NSE Zydus Lifesciences Limited

-61.05 (-6.91%)

USD 891.92B
AUROPHARMA:NSE Aurobindo Pharma Limited

-1.30 (-0.11%)

USD 674.02B
ABBOTINDIA:NSE Abbott India Limited

-240.00 (-0.78%)

USD 653.01B
ALKEM:NSE Alkem Laboratories Limited

+36.80 (+0.75%)

USD 583.68B
GLENMARK:NSE Glenmark Pharmaceuticals Limit..

-20.10 (-1.46%)

USD 434.87B

ETFs Containing LUPIN:NSE

DRFE:CA Desjardins RI Emerging Ma.. 0.00 % 0.00 %

-0.22 (-0.98%)

CAD 0.16B

Market Performance

  Market Performance vs. Industry/Classification (Drug Manufacturers - Specialty & Generic) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -18.68% 58% F 62% D
Dividend Return N/A N/A N/A N/A N/A
Total Return -18.68% 58% F 62% D
Trailing 12 Months  
Capital Gain 19.30% 73% C 82% B
Dividend Return 0.50% 47% F 42% F
Total Return 19.79% 73% C 82% B
Trailing 5 Years  
Capital Gain 172.54% 53% F 37% F
Dividend Return 4.04% 31% F 19% F
Total Return 176.58% 53% F 37% F
Average Annual (5 Year Horizon)  
Capital Gain 25.52% 52% F 42% F
Dividend Return 26.09% 49% F 42% F
Total Return 0.56% 57% F 45% F
Risk Return Profile  
Volatility (Standard Deviation) 54.29% 40% F 44% F
Risk Adjusted Return 48.05% 48% F 33% F
Market Capitalization 925.89B 94% A 95% A

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector